Niu Technologies, a leading smart urban mobility provider, will announce its third quarter 2026 financial results on November 16, 2026, before the U.S. market opens. The company will host a conference call the same day to discuss the results and business outlook. Investors can access the financial reports and webcast on Niu's investor relations website. This update is important for tracking the company's performance in the growing electric mobility market.
Niu Technologies plans to report its third quarter 2026 financial results on November 16, 2026. For readers following Consumer Cyclical stocks, here is Pluang's market snapshot as of Oct 19, 2026 15:11 WIB: of 134 priced US stocks in this sector, 72 rose and 29 fell. Notable movers include JMKE at USD 17.68 with a 1-day change of -1.50%, BBWI at USD 20.44 with +1.49%, and XPEV at USD 9.36 with +1.41%.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
